We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Invitation Homes
INVH
$17.6B
| $17.4M | 0.03% |
627,572
-658,203
| -51% | -$18.4M |
|
477
Carnival Corporation Ltd
CCL
$38B
| $17.4M | 0.03% |
568,391
-17,602
| -3% | -$491K |
|
478
Marathon Petroleum
MPC
$91.7B
| $17.3M | 0.03% |
106,145
-789
| -0.7% | -$147K |
|
|
P
479
Everpure Inc
P
$25B
| $17.1M | 0.03% |
255,124
+505
| +0.2% | +$42.2K |
|
480
Labcorp
LH
$25.9B
| $17.1M | 0.03% |
68,049
-495
| -0.7% | -$131K |
|
481
Arcutis Biotherapeutics
ARQT
$3.5B
| $17M | 0.03% |
586,397
-88,637
| -13% | -$2.27M |
|
482
WEC Energy
WEC
$35.8B
| $17M | 0.03% |
161,181
+3,628
| +2% | +$402K |
|
483
Adaptive Biotechnologies
ADPT
$3.87B
| $17M | 0.03% |
1,046,510
+52,543
| +5% | +$858K |
|
|
EXE
484
Expand Energy Corp
EXE
$21.4B
| $17M | 0.03% |
153,748
-768
| -0.5% | -$85.2K |
|
|
ECG
485
Everus Construction Group
ECG
$6.28B
| $16.9M | 0.03% |
197,743
+85,660
| +76% | +$7.66M |
|
486
lululemon athletica
LULU
$13.6B
| $16.9M | 0.03% |
81,167
-1,645
| -2% | -$298K |
|
487
Cincinnati Financial
CINF
$26.8B
| $16.8M | 0.03% |
103,069
-5,629
| -5% | -$912K |
|
488
IHS Holding
IHS
$2.76B
| $16.7M | 0.03% |
2,232,200
-155,215
| -7% | -$1.07M |
|
|
NUVL
489
DELISTED
Nuvalent
NUVL
| $16.6M | 0.03% |
165,177
+88,489
| +115% | +$8.73M |
|
490
Mueller Water Products
MWA
$3.9B
| $16.5M | 0.03% |
694,014
-41,255
| -6% | -$1.02M |
|
491
Kiniksa Pharmaceuticals
KNSA
$6.1B
| $16.5M | 0.03% |
400,598
+241,876
| +152% | +$9.7M |
|
492
Ball Corp
BALL
$17.4B
| $16.5M | 0.03% |
311,876
-13,888
| -4% | -$684K |
|
493
Dollar General
DG
$28.1B
| $16.5M | 0.03% |
124,415
-10,526
| -8% | -$1.17M |
|
494
iShares Broad USD High Yield Corporate Bond ETF
USHY
$29.3B
| $16.4M | 0.03% |
439,860
+92,622
| +27% | +$3.47M |
|
495
Deckers Outdoor
DECK
$13.6B
| $16.4M | 0.03% |
158,659
-126,184
| -44% | -$11.8M |
|
496
Phillips 66
PSX
$84.4B
| $16.4M | 0.03% |
127,106
-969
| -0.8% | -$130K |
|
497
Twilio
TWLO
$29B
| $16.4M | 0.03% |
115,153
+1,182
| +1% | +$146K |
|
498
Live Nation Entertainment
LYV
$42.7B
| $16.4M | 0.03% |
114,850
-676
| -0.6% | -$97.2K |
|
499
Idacorp
IDA
$7.86B
| $16.3M | 0.03% |
128,747
-1,707
| -1% | -$222K |
|
500
Camtek
CAMT
$6.4B
| $16.2M | 0.03% |
152,657
-38,126
| -20% | -$4.28M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.